Todos Medical receives two letters of approval from the USPTO for

New York, NY and Tel Aviv, ISRAEL, September 30, 2022 (GLOBE NEWSWIRE) – via NewMediaWire — All Medical, Ltd. TOMDF, a comprehensive medical diagnostics and related solutions company, announced today that it has received two letters of acceptance from the United States Patent & Trademark Office (USPTO) for patent applications covering the company’s Fourier Transformed Infrared (FTIR) pan for all biochemical infrared analysis (TBIA) Cover -Cancer Blood Diagnostics Platform. The approval notices apply to patent applications titled 1) “Infrared (IR) Spectroscopy System” and 2) “Infrared Analysis of Benign Tumors”. The company has already received CE Mark for its TBIA blood diagnostic test for breast cancer and colon cancer.

The allowable key claim for the Infrared (IR) spectroscopy system patent application concerned the system for collecting blood, obtaining the FTIR spectrum of peripheral blood lymphocytes and an output unit configured to produce an output indicative of the presence of a solid tumor. The claim, which was allowed for the Analysis of Benign Tumors patent application, related to the conditions necessary to collect consistent data in order to achieve actionable results.

“The approval of these two groundbreaking intellectual properties underlying the Company’s TBIA FTIR pan-cancer diagnostic platform, which we believe will ultimately outperform the liquid biopsy platform for routine testing in asymptomatic and early-stage cancer patients, including tests such as Illumina’s Galleri will ®,” said Gerald Commissiong, President and CEO of Todos Medical. “As we prepare to launch our Videssa breast cancer test in 2023, it will be very important to collect TBIA FTIR data from every patient that has been tested with Videssa so that we can further develop the TBIA-FTIR algorithm to collect enough data for submission to the FDA. This platform will allow us to test for multiple cancers from the same blood sample as spectroscopy in the Is so powerful compared to more traditional antibody-based assays…